DMK Pharmaceuticals Corp DMKPQ

Healthcare

DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.

PINL:DMKPQ - Post by User

DMK Pharmaceuticals Corp

<< Previous

Bullboard Posts

Next >>

Post by coolfooldumbguyon Dec 10, 2019 2:21pm

178 Views

Post# 30440615

added more of this one

it is way oversold,so I am using DCA,dollar cost averaging,for my purchases,buying up small amounts on a daily basis this month until my holdings are completed,so glta shareholders.

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle